Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06048484 · ClinicalTrials.gov registry record · Phase 2

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

A Phase 2 study of Pancreatic Ductal Adenocarcinoma, sponsored by Gulam Manji.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
5
Study locations

NCT06048484 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Gulam Manji. The registered enrollment target is 60 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06048484, a Phase 2 study of Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Gulam Manji.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs will work in concert with radiation therapy to kill cancer cells. The specific goal of this study is to ensure that treatment with zimberelimab and stereotactic body radiation therapy (SBRT) alone or in combination with quemliclustat (a drug which blocks CD73), with or without etrumadenant (a drug which blocks the A2a/b) given before surgery is safe and if it can further increase the immune response against the tumor.

Conditions Studied

Pancreatic Ductal Adenocarcinoma

Interventions

  • DRUG Zimberelimab
  • DRUG Quemliclustat
  • DRUG Modified FOLFIRINOX
  • DRUG Etrumadenant
  • RADIATION Stereotactic body radiotherapy (SBRT)

Study Locations (5)

New York

  • Northwell Health R.J. Zuckerberg Cancer Center - Lake Success
  • Columbia University Irving Medical Center - New York

North Carolina

  • UNC Hospitals, The University of North Carolina at Chapel Hill - Chapel Hill

Pennsylvania

  • University of Pennsylvania, Abramson Cancer Center - Philadelphia

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-05-10
Est. Completion 2027-04
Phase Phase 2

Sponsor

Gulam Manji

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06048484

The ClinicalTrials.gov registry entry for NCT06048484 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (90% lower). The listed sponsor is Gulam Manji, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Zimberelimab is the first listed.

NCT06048484 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06048484 about?

NCT06048484 is a clinical study titled "Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma". The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs ...

What is the current status of trial NCT06048484?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-05-10. Estimated completion is 2027-04.

What conditions does trial NCT06048484 study?

This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.

What interventions are being tested in trial NCT06048484?

The interventions under investigation include: Zimberelimab (DRUG), Quemliclustat (DRUG), Modified FOLFIRINOX (DRUG), Etrumadenant (DRUG), Stereotactic body radiotherapy (SBRT) (RADIATION).

Who is sponsoring clinical trial NCT06048484?

This trial is sponsored by Gulam Manji, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06048484 being conducted?

This trial has 5 study locations across New York, North Carolina, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Ductal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.